Context The molecular subtype of breast tumours plays a major role in cancer prognosis and treatment options. There was no significant association found between SES and tumour subtype in French ladies at diagnosis. Ladies more than 75 years were less likely to have a TN and HR+/HER2+ breast tumor (OR = 0.66; CI95% = [0.46C0.94] and OR = 0.51; CI95% = [0.37C0.70] respectively). Ladies with TN tumour subtype experienced significantly less lymph node invasion when compared to HR+/HER2- subtype (OR = 0.71; CI95% = [0.54C0.92]). Summary No significant association was found between socioeconomic status and molecular subtype. Further studies are needed to clarify the mechanisms associated with developing each tumour subtype. Intro Breast tumor is the most common tumor among women in the entire world [1]. In France, about 50 000 ladies are diagnosed with breast tumor each year [2]. Breast tumours are classified into one of four clinically relevant molecular subtypes based on the joint status of the hormone receptors (oestrogen and progesterone) and human being epidermal growth factors receptor 2 (HER2) [3,4]. The hormone receptors (HR) and HER2 receptors are said to be positive if they are overexpressed in a tumour cell. The HR-positive tumours are the most common at diagnosis (80%), and the HER2-positive represents about 15C20% [5]. Receptor screening is usually readily available and performed routinely during breast malignancy diagnosis in France. The information on receptors is usually of clinical importance since treatment options are selected based on the joint receptor status. Each subtype has its own unique histological profile and risk factors [2]. The HER2+ tumours are known to be very aggressive and have poor survival in women [3]. Nowadays, the HR+/HER2+ subtype CP-690550 has a better prognosis, particularly in metastatic tumours because it has molecular targets for hormone therapy as well as other targeted treatments like Trastuzumab (HerceptinTM) [4]. Tumours which are unfavorable for both hormone receptors (HR) and HER2 receptor are called triple unfavorable tumours (TN). These TN tumours have the worst prognosis and impact more often underprivileged women in the USA [5,6]. Socioeconomic status influences the exposure to several risk factors which could change tumour biology [7,8]. It has been shown that women in high poverty areas tend to secrete more oestrogen when compared to women with a more affluent socioeconomic status [8]. Few studies have looked at the association between socioeconomic status and tumour subtypes [9C14]. Among these studies, there have been registry based analyses where a significant association between the SES and the breast malignancy subtype in American women was observed, in particular among the TN cases who experienced higher odds of being in the lowest socioeconomic stratum when compared to the other subtypes To this date no study has been carried out investigating this association in women residing in France. Our objective is to study the association between socioeconomic status and breast malignancy subtype at diagnosis among women in the French county of C?te dOr. Methods Study populace CP-690550 A population-based study was undertaken using data from your C?te dOr breast and gynaecological malignancy registry. This Breast and Gynaecological Malignancy Registry is the only one in France that focuses on breast and gynaecological cancers. It has been collecting comprehensive population-based data since 1982 in this area located in the northeast of France. Women with main invasive breast malignancy and living in the rural county of C?te dOr at CP-690550 the time of diagnosis were retrospectively determined from January 2003 to December 2013 to be included in this study. The year 2003 is the 12 months that this registry began collecting systematically data for HER2. The data extraction which was performed was anonymized prior Rabbit Polyclonal to CSGLCAT to reception of the data by the investigators and did CP-690550 not carry the patients names or personal information which could identify them (name initials). The registry has the necessary regulatory agreements to use.
Tag Archives: CP-690550
Categories
- 34
- 5- Receptors
- A2A Receptors
- ACE
- Acetylcholinesterase
- Adenosine Deaminase
- Adenylyl Cyclase
- Adrenergic ??2 Receptors
- Alpha2 Adrenergic Receptors
- Annexin
- Antibiotics
- ATPase
- AXOR12 Receptor
- Ca2+ Ionophore
- Cannabinoid
- Cannabinoid (GPR55) Receptors
- CB2 Receptors
- CCK Receptors
- Cell Metabolism
- Cell Signaling
- Cholecystokinin2 Receptors
- CK1
- Corticotropin-Releasing Factor1 Receptors
- DHCR
- DMTases
- DNA Ligases
- DNA Methyltransferases
- Dopamine D1 Receptors
- Dopamine D3 Receptors
- Dopamine D4 Receptors
- Endothelin Receptors
- EP1-4 Receptors
- Epigenetics
- Exocytosis & Endocytosis
- Fatty Acid Synthase
- Flt Receptors
- GABAB Receptors
- GIP Receptor
- Glutamate (Kainate) Receptors
- Glutamate (Metabotropic) Group III Receptors
- Glutamate (NMDA) Receptors
- Glutamate Carboxypeptidase II
- Glycogen Phosphorylase
- Glycosyltransferase
- GnRH Receptors
- Heat Shock Protein 90
- hERG Channels
- Hormone-sensitive Lipase
- IKK
- Imidazoline Receptors
- IMPase
- Inositol Phosphatases
- Kisspeptin Receptor
- LTA4 Hydrolase
- M1 Receptors
- Matrixins
- Melastatin Receptors
- mGlu Group III Receptors
- mGlu5 Receptors
- Monoamine Oxidase
- Motilin Receptor
- My Blog
- Neutrophil Elastase
- Nicotinic (??4??2) Receptors
- NKCC Cotransporter
- NMU Receptors
- Nociceptin Receptors
- Non-Selective
- Non-selective 5-HT
- OP3 Receptors
- Opioid, ??-
- Orexin2 Receptors
- Other
- Other Oxygenases/Oxidases
- Other Transcription Factors
- p38 MAPK
- p53
- p56lck
- PAF Receptors
- PDPK1
- PKC
- PLA
- PPAR
- PPAR??
- Proteasome
- PTH Receptors
- Ras
- RNA Polymerase
- Serotonin (5-HT2B) Receptors
- Serotonin Transporters
- Sigma2 Receptors
- Sodium Channels
- Steroid Hormone Receptors
- Tachykinin NK1 Receptors
- Tachykinin NK2 Receptors
- Tachykinin, Non-Selective
- Telomerase
- Thyrotropin-Releasing Hormone Receptors
- Topoisomerase
- trpp
- Uncategorized
- USP
Recent Posts
- 2012) using the Phenotypic Characteristic Search for human strains with markers for resistance to Adamantane, Oseltamivir, or both drugs
- Tissue were homogenized into single-cell suspensions and put through red bloodstream cell lysis
- A phase I/II study investigated the safety and efficacy of concurrent local palliative RT and durvalumab (PD-L1 inhibitor) in 10 patients with unresectable or metastatic advanced solid tumors [136]
- We believe that this hypothesis-generating study could open new avenues for exploring oxidative stress as a potential pathogenetic and, hypothetically, therapeutic target for mitigating CLL strong class=”kwd-title” Keywords: Leukemia, Lymphocytic, Gilbert’s, Syndrome Gilbert’s syndrome (GS) is the most common inherited disorder of bilirubin glucuronidation
- Such costs aren’t simple for tertiary-care hospitals in growing countries sometimes, since these already are powered by minimal budget which switches into provision of fundamental medical services mostly, laboratory, radiology, pharmacy services, and bed space
Tags
a 67 kDa type I transmembrane glycoprotein present on myeloid progenitors
and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes
Apoptosis
bladder
brain
breast
cell cycle progression
cervix
CSP-B
Cyproterone acetate
EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck
EM9
endometrium
erythrocytes
F3
Goat polyclonal to IgG H+L)
Goat polyclonal to IgG H+L)Biotin)
GRK4
GSK1904529A
Igf1
Mapkap1
monocytes andgranulocytes. CD33 is absent on lymphocytes
Mouse monoclonal to CD33.CT65 reacts with CD33 andtigen
Palomid 529
platelets
PTK) or serine/threonine
Rabbit Polyclonal to ARNT.
Rabbit polyclonal to BMPR2
Rabbit Polyclonal to CCBP2.
Rabbit Polyclonal to EDG4
Rabbit polyclonal to EIF4E.
Rabbit polyclonal to IL11RA
Rabbit polyclonal to LRRIQ3
Rabbit Polyclonal to MCM3 phospho-Thr722)
Rabbit Polyclonal to RBM34
SB 216763
SKI-606
SNX-5422
STK) kinase catalytic domains. Epidermal Growth factor receptor
stomach
stomach and in squamous cell carcinoma.
TNFSF8
TSHR
VEGFA
vulva